drugset / Trial / NCT00270400
A Safety Study Comparing Natrecor (Nesiritide) Versus Dobutamine Therapy for Worsening Congestive Heart Failure
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the effects on heart rate and ventricular arrhythmias (irregular heart beats) of two doses of Natrecor® (a recombinant form of the natural human peptide normally secreted by the heart in response to heart failure) versus dobutamine, during the first 24 hours of treatment of decompensated congestive heart failure (CHF).
Timeline
- Start
- 1998-08
- Primary completion
- —
- Completion
- 1999-02
Publications
- Results Burger AJ, Horton DP, LeJemtel T, Ghali JK, Torre G, Dennish G, Koren M, Dinerman J, Silver M, Cheng ML, Elkayam U; Prospective Randomized Evaluation of Cardiac Ectopy with Dobutamine or Natrecor Therapy. Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study. Am Heart J. 2002 Dec;144(6):1102-8. doi: 10.1067/mhj.2002.125620.
- Nearing BD, Wellenius GA, Mittleman MA, Josephson ME, Burger AJ, Verrier RL. Crescendo in depolarization and repolarization heterogeneity heralds development of ventricular tachycardia in hospitalized patients with decompensated heart failure. Circ Arrhythm Electrophysiol. 2012 Feb;5(1):84-90. doi: 10.1161/CIRCEP.111.965434. Epub 2011 Dec 8.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nesiritide | Protein / enzyme biologic | 0.015 ug/kg | Intravenous |
| Subject | Nesiritide | Protein / enzyme biologic | 0.03 ug/kg | Intravenous |